Introduction

Milk thistle (Silybum marianum) is one of the few herbal drugs whose excellent pharmacological profile readily lends itself to proof of clinical efficacy1. Silymarin, the seed extract of milk thistle, has been widely used to maintain liver health and treat liver disorders2. Different dosage forms of silymarin have been reported3, Determination of dehydrosilymarin in rabbit plasma by RP-HPLC

In our study, the plasma concentrations of dehydrosilymarin were determined by a HPLC-UV method. Dehydrosilymarin was separated at 25 °C by a C18 column (VP-ODS, 150 mm×4.6 mm, 5 μm, Shimazu, Japan) and analyzed at 255 nm. The mobile phase was composed of methanol/double distilled water/methanoic acid in a volume ratio of 57/43/0.2 (v/v/v) at a flow rate of 1.2 mL/min.

After plasma samples had been thawed, dehydrosilymarin in rabbit plasma was extracted by liquid-liquid extraction procedures as follows: 200 μL of rabbit plasma was added to a 10 mL polypropylene screw-capped conical tube, which was followed by the addition of 20 μL of internal standard solution (α-naphthol, 100 μg/mL in methanol), 20 μL of methanol, 50 μL of a 0.5 mol/L K2HPO4 solution and 5 mL of anhydrous diethyl ether, in order. After vortexing for 2 min, the mixture was centrifuged at 3000 revolutions per minute (Clements GS 200 centrifuge) for 10 min. The organic layer was transferred to another tube and evaporated under a light stream of nitrogen at 37 °C. The residues were re-suspended in 200 μL of mobile phase and vortexed for 30 s. Aliquots (20 μL) of the supernatant were injected for HPLC analysis. Quantitation was based on the peak area ratio (ADSLY/AIS). Linearity was observed over the concentration range of 0.22–55 μg/mL. Moreover, the limit of detection (S/N≥3), within-day and between-day precisions, and recovery method of dehydrosilybin in rabbit plasma were also determined by HPLC.

Bioavailability studies

The bioavailability of dehydrosilymarin-loaded proliposomes was compared with that of dehydrosilymarin suspension. Dehydrosilymarin-loaded proliposomes were diluted with distilled water to form liposomal suspension, while a dehydrosilymarin suspension was prepared by dispersing the milling drug in water by ultrasonic resuspension. Six rabbits weighing 2.5±0.5 kg (supplied by the Laboratory Animal Center of Jiangsu University) were randomly divided into two groups and fasted overnight prior to the experiment, while water was available ad libitum following the regulations for the administration of affairs concerning experimental animals (State Council of the China, 1988). All research protocols were approved by the Research Ethics Committee of Jiangsu University. The rabbits in each group were given the dehydrosilymarin liposomal suspension and dehydrosilymarin suspension through gavage administration for a dose of dehydrosilymarin of 80 mg/kg. Approximately 1.2 mL of blood was collected through the peripheral ear vein into heparinized tubes at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h. Blood samples were immediately separated by centrifugation (3000 revolutions per minute for 10 min), and subsequent plasma samples were stored at -20 °C until further analysis.

The peak concentration (Cmax) and peak time (tmax) were derived directly from the experimental points as raw data. The other pharmacokinetic parameters were calculated by the software program BAPP 2.3 (Nan**g Baikang Pharmaceutical Co Ltd, China).

Results

Synthesis of dehydrosilymarin

The experimental results demonstrated that reaction time and reaction temperature could affect the synthetic product. Too long a reaction time or too high a reaction temperature would result in carbonation. Finally, dehydrosilymarin was prepared at 90 °C under reflux for 77 h with stirring. The yield of dehydrosilymarin was generally approximately 70%–80%.

Preparation of dehydrosilymarin-loaded proliposomes

The shape, outward appearance and entrapment efficiency of proliposomes were characterized. The results proved that the proliposomes was smooth and spherieal in appearance with better dispersion and high entrapment efficiency. The proliposomes can be administered orally in the form of powders or filled into capsules.

Characteristics of dehydrosilymarin in dehydrosilymarin-loaded proliposomes

The dehydrosilymarin-loaded proliposomes turned into a liposomal suspension when diluted with distilled water. The morphological characterization of dried dehydrosilymarin-loaded liposomes is shown in Figure 1. The observed liposome droplets were spherical.

Figure 1
figure 1

Transmission electron micrograph for liposomal dispersion at×4000 magnification.

Full size image

Because the particle size of the preparation made a large impact on its in vitro and in vivo performance, we measured the size distribution of dehydrosilymarin-loaded proliposomes after diluting them with distilled water. The result is displayed in Figure 2. It can be seen from the picture that the particle size of dehydrosilymarin-loaded liposomes was distributed in the range of 7 to 50 nm, and the average diameter was 15.5 nm, which was consistent with the results of the TEM analysis. We were pleased to note that the relatively small size of liposomes may have the potential to facilitate the oral absorption of dehydrosilymarin.

Figure 2
figure 2

Size distribution of dehydrosilymarin-loaded proliposomes.

Full size image

The content of dehydrosilymarin in dehydrosilymarin-loaded proliposomes after hydration with water was 25.00±5.93 μg/mL (n=3), and the drug loading percentage was approximately 12.5%.

The entrapment efficiency of dehydrosilymarin in proliposomes was 81.59%±0.24% (n=3), which was predominately dependent on the dehydrosilymarin/phospholipid ratio and sodium cholate/phospholipid. Increasing the amount of phospholipid in addition to adding a moderate amount of surfactants in the prescription can increase drug encapsulation efficiency. However, excessive amounts of phospholipid not only increased the viscosity of the final preparation, but also yielded a sharp reduction in the drug loading efficiency, while the toxicity of surfactant also limited its dosage.

In vitro release studies

As shown in Figure 3, the release of dehydrosilymarin from suspension and proliposomes was poor in pH 1.2, with less than 20% of drug going into the medium after 12 h. Despite a slightly higher release of the drug from suspension than from proliposomes in pH 1.2, the release of the drug from proliposomes was tremendously increased compared with that of the drug suspension in pH 6.8. Furthermore, dehydrosilymarin was continuously released from proliposomes in PBS, and the cumulative release ratio was up to 86.41% at 12 h.

Figure 3
figure 3

In vitro release profiles of dehydrosilymarin from suspension and proliposomes in different release mediums containing 0.1 % of sodium dodecyl sulfate as surfactant. (♦), suspension in 900 mL HCl (pH 1.2); (▴), proliposomes in 900 mL HCl (pH 1.2); (▪), suspension in 900 mL phosphate buffered saline (pH 6.8); (•), proliposomes in 900 mL phosphate buffered saline (pH 6.8).

Full size image

Rabbit bioavailability experiments

Dehydrosilybin, the main active ingredient of dehydrosilymarin, was measured as the indicator of bioavailability. In accordance with previous pretreatment and chromatographic conditions, blank rabbit plasma, blank rabbit plasma spiked with dehydrosilybin and a sample after oral administration of dehydrosilymarin-loaded proliposomes were analyzed by HPLC (Figure 4). Good separation of the main peak and the hybridized peak was achieved in the present chromatographic conditions. The retention time of internal standard and dehydrosilybin was approximately 7.5 and 17.5 min, respectively.

Figure 4
figure 4

Typical chromatograms of dehydrosilybin: (A) blank rabbit plasma; (B) blank rabbit plasma spiked with dehydrosilybin; (C) a sample after oral administration of dehydrosilymarin-loaded proliposomes.

Full size image

Within the concentration range of 0.22–55 μg/mL, the peak area ratio (R) of dehydrosilybin as a whole compared to the internal standard correlated well to the spiked plasma concentration: R=0.5691C–0.0058, r=0.9991. The lowest limit of quantification for the determination of dehydrosilybin in rabbit plasma was found to be 50 ng/mL. The relative standard deviations of intra-day and inter-day assay and the spiked recoveries of dehydrosilybin from rabbit plasma are shown in Table 1.

Table 1 The precision and recovery tests of dehydrosilybin in rabbit plasma. Data expressed as mean±SD. n=5.
Full size table

The oral bioavailabilities of dehydrosilymarin-loaded proliposomes and drug powders were compared in rabbits. Figure 5 shows the drug plasma profiles after gavage administration of dehydrosilymarin-loaded liposomal suspension and dehydrosilymarin suspension (n=3). The liposomal suspension was obtained by dispersing proliposome powders in distilled water. The dehydrosilymarin suspension was prepared by mixing dehydrosilymarin powders with distilled water. As seen in the graph, the plasma concentration of dehydrosilymarin suspension was at a low and stable level at 12 h, although a slight peak was observed at 2 h. The drug concentration of dehydrosilymarin-loaded liposomal suspension was much higher than that of dehydrosilymarin suspension at every time point, and doubly sharp peaks at maximum concentrations were seen as a result, which is a characteristic of enterohepatic circulation24. Moreover, Cmax was approximately 0.57 μg/mL after the dehydrosilymarin suspension was orally administered to rabbits with a tmax of 2.00 h. Meanwhile, after oral administration of the dehydrosilymarin-loaded liposomal suspension, the value of Cmax was approximately 2.83 μg/mL with a tmax of 0.50 h. In conclusion, the dehydrosilymarin-loaded proliposomes took less time to reach the maximum plasma concentration in comparison with the dehydrosilymarin suspension, and the Cmax was approximately 4.96-fold higher than that of the dehydrosilymarin suspension.

Figure 5
figure 5

Mean plasma concentration-time curves of dehydrosilybin after oral administration of dehydrosilymarin suspension and dehydrosilymarin-loaded liposomal suspension (n=3, 80 mg/kg). (♦), dehydrosilymarin suspension; (▪), dehydrosilymarin-loaded liposomal suspension. Data expressed as mean±SD.

Full size image

The pharmacokinetic parameters calculated by the software program BAPP 2.3 are shown in Table 2. It was found that the curves plotting the plasma concentration of dehydrosilybin over time after the oral administration of the dehydrosilymarin suspension and dehydrosilymarin-loaded liposomal suspension in rabbits were both in accordance with a non-compartment model. As shown in Table 2, dehydrosilymarin-loaded proliposomes exhibited higher absorption in 12 h. The AUCt of the vesicle was approximately 2.29-fold higher than that of the dehydrosilymarin suspension, which meant that the relative bioavailability of dehydrosilymarin-loaded proliposomes was approximately 228.85%.

Table 2 Pharmacokinetic parameters of dehydrosilymarin suspension and dehydrosilymarin-loaded liposomal suspension (n=3, 80 mg/kg). Data expressed as mean±SD.
Full size table

In vitro and in vivo correlation

The in vitro and in vivo correlation was analyzed using the software program BAPP 2.3. The Wegner-Nelson method was applied to compare the in vitro drug release curve with the in vivo absorption curve. The linear regression equations of drug powders and proliposomes in vivo versus release percentages in vitro after 1–12 h were calculated. As presented in Table 3, Fr was the in vitro release percentage, and Fa was the in vivo absorption percentage. Apparently, the in vivo absorption of dehydrosilymarin and proliposomes significantly correlated with the in vitro drug release at both pH 1.2 and pH 6.8; the in vitro release study could be used to help predict the drug absorption in vivo.

Table 3 The correlative results of dehydrosilymarin powders and dehydrosilymarin-loaded proliposomes in vitro and in vivo (Checked the critical value table for r, when the degree of freedom v was 8, critical value r8, 0.05=0.632, which showed the correlation coefficients of regression equations of drugs r>r8, 0.05).
Full size table

Discussion

Silymarin is a flavonoid complex extracted from seeds of the milk thistle (Silybum marianum)25 that contains the main active compounds silybin, silychristine and silydianin2. Silybin, the major active moiety, has been widely used in the prevention and treatment of various liver diseases. Nevertheless, the bioavailability of silybin is rather limited due to its low solubility in water26, 27. The equilibrium solubility of silybin in water is approximately 51.06 μg/mL at 37 °C. Therefore, some preparations have been made in recent years to improve the solubility and bioavailability of silybin, including phospholipid complexes28, sodium cholate/phospholipid complexes and povidone-sodium cholate-phospholipid mixed micelles29, 30. Recently, 2,3-dehydrosilybin, an oxidized form of silybin, has been reported to exhibit a significantly greater antioxidant and anticancer activity in comparison with silybin22. We synthesized dehydrosilymarin following the method originally designed for the preparation of dehydrosilybin and confirmed that dehydrosilymarin showed increased antiradical and antioxidative capacities than those of silybin, dehydrosilybin and silymarin5. The compositions of dehydrosilymarin were studied with HPLC-MS analysis (data not shown).

Prior to the preparation of proliposomes, we initially produced dehydrosilymarin-phospholipid complexes to improve the lipid solubility of dehydrosilymarin, which was convenient for the formation of liposomes. The results revealed that the mass ratio of dehydrosilymarin to phospholipid had the most significant effect on entrapment efficiency of proliposomes. With an increasing amount of phospholipid, the encapsulation efficiency of proliposomes was correspondingly increased. When the concentration of phospholipid reached a certain proportion, the encapsulation efficiency of proliposomes was mostly unchanged. Moreover, too high a concentration of phospholipid drastically decreased the drug loading percentage, and gradually increased the viscosity of the final preparation. As a result, optimal drug-lipid ratio was determined to be 1:3.

The cumulative release of dehydrosilymarin from proliposomes in pH 6.8 and pH 1.2 was compared to simulate the environment of the stomach and small intestine. Above all, it was important to disperse proliposomes with water to form a liposomal suspension; otherwise, the proliposomes powders would stick to the dialysis bag, thus affecting drug release from the liposomal suspension.

To simulate the in vivo release profiles of the vesicles, minute amounts of surfactant are typically incorporated into the release medium. In this study, 0.1% sodium dodecyl sulfate was employed as a surfactant, mimicking the presence of bile salts, which are the natural surfactants in the gastrointestinal tract.

The in vitro study showed that the release of dehydrosilymarin from proliposomes in pH 1.2 was relatively poor and that the drug was continuously released from proliposomes in pH 6.8. These results might be explained by the fact that the lipophilic drug was held by the small fragment of the liposomal membrane. Therefore, the drug that was loaded in the lipid membrane was released mainly through dissolution and diffusion from the lipid bilayer, which could decrease the release rate of dehydrosilymarin from proliposomes31, 32. However, the higher accumulative release ratio of proliposomes in pH 6.8 was attributed to the fact that the formulation afforded a greater solubilizing effect on the drug, thus enhancing the release rate.

A study on the pharmacokinetics of dehydrosilymarin-loaded proliposomes in rabbits after oral administration was also conducted. The results indicated that, in rabbits, the absorption profile of the proliposomes was much better than that from the suspension. We speculated that the underlying mechanism for the improvement of oral absorption of proliposomes could be explained by the relatively small size of the proliposomes, the presence of bile salts and the similarity between liposomal lipid bilayers and biomembranes. Therefore, we deduced that proliposomes, as a new dosage form, provide a promising method to enhance the oral absorption of hydrophobic drugs. As noted in the results, the double peak phenomenon was observed for the plasma concentration versus time curve for dehydrosilymarin-loaded proliposomes. Enterohepatic cycling is known to be responsible for secondary peaks in relation with bile salts, the component of proliposomes.

Interestingly, although the plasma concentration of the dehydrosilymarin suspension was low, the MRT was relatively long (about 21.33 h after oral administration). However, we failed to detect the existence of the drug after oral administration of the same dosage of silymarin, which meant that the absorption of dehydrosilymarin in vivo was obviously better than silymarin. The reasons that dehydrosilymarin exhibited better bioavailability will be investigated in our further research.

In summary, the current study demonstrates that the oral bioavailability of the new drug dehydrosilymarin was significantly enhanced by proliposomes (a polyphase dispersed system composed of phospholipids, cholesterol, isopropyl myristate, and sodium cholate). The relatively small size of proliposomes, the presence of bile salts and the similarity between liposomal lipid bilayers and biomembranes might be responsible for the improved oral absorption. Moreover, the results in vivo significantly correspond with the in vitro release results, suggesting that the in vitro release study can be used to help predict drug absorption in vivo. However, the absorption mechanism of dehydrosilymarin will require further investigation.

Author contribution

**-ming XU, Jiang-nan YU, and Yan-ru GE designed the research; Shan-shan TONG and Chang CHU performed the research; **-ming XU, Shan-shan TONG, Ying XU, Li WANG, Chang CHU, and Min FU analyzed the data; Chang CHU wrote the paper.